Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) is a disorder that involves the activation of alveolar macrophages triggering the innate immune system. The parenchymal lung injury seen in ARDS is a result of many proinflammatory elevations including interleukin-6. There remains no effective standard of c...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandra Petrillo, Noa Biran, Sean Sadikot
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Critical Care
Online Access:http://dx.doi.org/10.1155/2020/8832986
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832546896295493632
author Alessandra Petrillo
Noa Biran
Sean Sadikot
author_facet Alessandra Petrillo
Noa Biran
Sean Sadikot
author_sort Alessandra Petrillo
collection DOAJ
description Acute respiratory distress syndrome (ARDS) is a disorder that involves the activation of alveolar macrophages triggering the innate immune system. The parenchymal lung injury seen in ARDS is a result of many proinflammatory elevations including interleukin-6. There remains no effective standard of care of ARDS, and current treatments at this time currently do not target the immunological mechanisms or pathways involved. Treatments involving this pathway should be further investigated as targeted treatment. We discuss a case of a patient with multiple myeloma who was hospitalized with drug-induced ARDS who had a rapid response to an anti-interleukin-6 monoclonal antibody.
format Article
id doaj-art-a74a78025090456fb7a4652a73963472
institution Kabale University
issn 2090-6420
2090-6439
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Case Reports in Critical Care
spelling doaj-art-a74a78025090456fb7a4652a739634722025-02-03T06:46:55ZengWileyCase Reports in Critical Care2090-64202090-64392020-01-01202010.1155/2020/88329868832986Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress SyndromeAlessandra Petrillo0Noa Biran1Sean Sadikot2Hackensack University Medical Center, Hackensack, NJ, USAHackensack University Medical Center, Hackensack, NJ, USAHackensack University Medical Center, Hackensack, NJ, USAAcute respiratory distress syndrome (ARDS) is a disorder that involves the activation of alveolar macrophages triggering the innate immune system. The parenchymal lung injury seen in ARDS is a result of many proinflammatory elevations including interleukin-6. There remains no effective standard of care of ARDS, and current treatments at this time currently do not target the immunological mechanisms or pathways involved. Treatments involving this pathway should be further investigated as targeted treatment. We discuss a case of a patient with multiple myeloma who was hospitalized with drug-induced ARDS who had a rapid response to an anti-interleukin-6 monoclonal antibody.http://dx.doi.org/10.1155/2020/8832986
spellingShingle Alessandra Petrillo
Noa Biran
Sean Sadikot
Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
Case Reports in Critical Care
title Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
title_full Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
title_fullStr Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
title_full_unstemmed Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
title_short Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
title_sort use of anti interleukin 6 receptor monoclonal antibody in drug induced acute respiratory distress syndrome
url http://dx.doi.org/10.1155/2020/8832986
work_keys_str_mv AT alessandrapetrillo useofantiinterleukin6receptormonoclonalantibodyindruginducedacuterespiratorydistresssyndrome
AT noabiran useofantiinterleukin6receptormonoclonalantibodyindruginducedacuterespiratorydistresssyndrome
AT seansadikot useofantiinterleukin6receptormonoclonalantibodyindruginducedacuterespiratorydistresssyndrome